SARS-CoV-2 antibody landscape following multiple vaccinations and infections during Omicron period

Background: Repeated COVID-19 vaccination effects on the immunogenicity, breadth, and durability of antibody responses across antigenically distinct SARS-CoV-2 variants remain incompletely understood. Method: Participants receiving >= five COVID-19 vaccine doses 2020-2025 were selected from a prospective cohort in Michigan. Serum IgG, IgM, and ACE2 percent inhibition were measured using multiplex assays. Baseline-adjusted immunogenicity, cross-reactivity, and formulation-specific antibody durability were evaluated using regression models. Result: Twenty-one participants were included (median: seven vaccine doses). For every two-fold increase in pre-vaccination IgG concentration, post-vaccination fold-rise was 34% (95% CI: 16%-48%), 43% (95% CI: 15%-62%), and 55% (95% CI: 21%-75%) lower following monovalent, bivalent, and 2023-24 vaccination, while baseline-adjusted immunogenicity showed no significant trends across successive vaccines. Antibody landscapes demonstrated broad cross-reactivity against ancestral and Omicron variants, with similar strain-specific IgG changes across ancestral, vaccine-matched, and antigenically distant strains, but greater heterogeneity in ACE2 inhibition. Formulation-specific waning models showed significant IgG declines following monovalent and bivalent vaccination (beta = -1.03, 95% CI: -1.51 to -0.55; P<0.001 and -1.00 , 95% CI: -1.71 to -0.30; P=0.007, respectively) and ACE2 inhibition declines following monovalent vaccination, while other formulations showed less consistent changes. Despite waning, antibody levels generally remained relatively high across variants up to 300 days post-vaccination, with formulation-specific differences in durability. Conclusion: Repeated COVID-19 vaccination maintained baseline-adjusted immunogenicity and broad cross-reactive antibody responses, with formulation-specific differences in durability. Higher baseline immunity was associated with smaller post-vaccination increases, suggesting repeated boosting continues to reinforce humoral immunity despite increasingly complex immune histories.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.16.26368199
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

SARS-CoV-2 antibody landscape following multiple vaccinations and infections during Omicron period

Arnold S. Monto, Emily Toth Martin, Yangyupei Yang, Amy P. Callear et al.
2 links
medRxiv
SARS-CoV-2 and COVID-19 Research
preprint

SARS-CoV-2 antibody landscape following multiple vaccinations and infections during Omicron period

Arnold S. Monto, Emily Toth Martin, Yangyupei Yang, Amy P. Callear, Elie-Tino Godonou, Casey L. Juntila-Raymond, Matthew Smith
preprint en

Abstract

Background: Repeated COVID-19 vaccination effects on the immunogenicity, breadth, and durability of antibody responses across antigenically distinct SARS-CoV-2 variants remain incompletely understood. Method: Participants receiving >= five COVID-19 vaccine doses 2020-2025 were selected from a prospective cohort in Michigan. Serum IgG, IgM, and ACE2 percent inhibition were measured using multiplex assays. Baseline-adjusted immunogenicity, cross-reactivity, and formulation-specific antibody durability were evaluated using regression models. Result: Twenty-one participants were included (median: seven vaccine doses). For every two-fold increase in pre-vaccination IgG concentration, post-vaccination fold-rise was 34% (95% CI: 16%-48%), 43% (95% CI: 15%-62%), and 55% (95% CI: 21%-75%) lower following monovalent, bivalent, and 2023-24 vaccination, while baseline-adjusted immunogenicity showed no significant trends across successive vaccines. Antibody landscapes demonstrated broad cross-reactivity against ancestral and Omicron variants, with similar strain-specific IgG changes across ancestral, vaccine-matched, and antigenically distant strains, but greater heterogeneity in ACE2 inhibition. Formulation-specific waning models showed significant IgG declines following monovalent and bivalent vaccination (beta = -1.03, 95% CI: -1.51 to -0.55; P<0.001 and -1.00 , 95% CI: -1.71 to -0.30; P=0.007, respectively) and ACE2 inhibition declines following monovalent vaccination, while other formulations showed less consistent changes. Despite waning, antibody levels generally remained relatively high across variants up to 300 days post-vaccination, with formulation-specific differences in durability. Conclusion: Repeated COVID-19 vaccination maintained baseline-adjusted immunogenicity and broad cross-reactive antibody responses, with formulation-specific differences in durability. Higher baseline immunity was associated with smaller post-vaccination increases, suggesting repeated boosting continues to reinforce humoral immunity despite increasingly complex immune histories.

medRxiv
University of Michigan (US)
Good health and well-being
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon